RESEARCH FOCUS
Investigate the role of the microbiota in digestive system cancers, metabolic syndrome, and rare metabolic disorders, as well as their pathogenic mechanisms. Develop microbiota-centered biomarkers and intervention strategies.
Using the microbiota as the core, conduct multiomics and phenomics research on the mentioned diseases and their sub-healthy populations. Establish their digital avatars for disease prediction and prevention.
The research mentioned above aims to develop a precision health research and development ecosystem that encompasses industry, academia, and research. This will expand the value of research and innovation from basic to clinical, from laboratory to patient care in hospital wards, and from hospitals to the community.
Recent Paper Publications
| Publication Date | Author | Article Title | Abstract | Journal Name | SCI Impact Factor |
| April 2025 (Accepted) | Professor Chun-Ying Wu and student Teng-Li Lin et al. | Psoriasis risk in atopic dermatitis patients treated with dupilumab: a population-based cohort study. | JAMA Dermatology | 11.5 | |
| April 17, 2025 | Professor Chun-Ying Wu and student Teng-Li Lin et al. | Cardiovascular disease risk in patients with psoriasis receiving biologics targeting | This study found that, compared with oral medications, psoriasis patients treated with biologics had a significantly lower risk of cardiovascular disease. In particular, the use of anti–TNF-α, anti–IL-17, and anti–IL-23 agents was associated with a reduced risk of cardiovascular disease, whereas anti–IL-12/23 showed no significant difference. These findings were consistent across different age groups, sexes, regions, and comorbidity profiles, supporting the potential cardiovascular benefits of biologics in the treatment of psoriasis. | PLOS Medicine | 10.5 |
| April 7, 2025 | Professor Chun-Ying Wu et al. | The development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. | This study presents consensus recommendations from gut microbiome experts in the Asia-Pacific region on the development of live biotherapeutic products (LBPs), covering three main aspects: the rationale for development, preclinical research, and clinical readiness. The experts recommend prioritizing strains derived from humans and food sources, and emphasize that the development process must include rigorous functional assessment, genetic monitoring, and safety testing. Clinical trials should be carefully designed and incorporate robust risk management to ensure the safety and efficacy of these products. | Gastroenterology & Hepatology | 23.0 |
| January 2025 | Professor Cheng-Yen Kao et al. | An Integrated Platform for Investigating Drug-Microbial Interactions to Support Pharmacomicrobiomics Studies | Talanta | ||
| December 2024 | Professor Li-Ling Wu et al. | Interleukin-1R1 deficiency worsens hepatocellular carcinoma while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells. | J Gastroenterol Hepatol. | ||
| November 28, 2024 | Professor Chun-Ying Wu and student Teng-Li Lin et al. | Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: A population-based cohort study | This study found that, compared with conventional therapies, patients with atopic dermatitis treated with dupilumab had a significantly lower risk of developing anxiety, depression, adjustment disorders, and sleep disorders within three years. These results were consistent across different age groups, sexes, races, and comorbidity profiles, with particularly pronounced effects observed in African American patients. Only the difference in the risk of attention-deficit/hyperactivity disorder (ADHD) was not statistically significant. | Ann Allergy Asthma Immunol | 5.8 |
| July 30, 2024 | Professor Chun-Ying Wu et al. | Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis | This study investigates the effects of short-chain fatty acids (SCFAs) on the skin phenotype, systemic inflammation, and gut microbiota of mice with psoriasis-like disease. Imiquimod (IMQ)-treated mice were used as a model, and a genomics approach was employed to analyze the effects of SCFAs or anti–IL-17 antibody on skin thickness, inflammatory markers, and fecal microbiota. The results showed that SCFAs improved IMQ-induced skin thickening, splenomegaly, and serum IL-17F levels, with effects comparable to anti–IL-17 therapy. SCFAs also increased microbial diversity and altered the composition of the gut microbiota, suggesting their involvement in processes such as carbohydrate degradation and phenylalanine metabolism. | Scientific reports |